Viral pathogens

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 40-46

  Ragni, M V ^a   Sherman, K E ^a,b   Jordan, J A ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

B19 parvovirus; Haemophilia; Hepatitis C; HIV; Transfusion; Viral pathogens

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BOCEPRAVIR; FERRITIN; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; APLASTIC ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PARVOVIRUS B19; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; PARVOVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; TREATMENT DURATION; VIRUS INACTIVATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BLOOD TRANSFUSION; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 77955016701     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02292.x     Document Type: Review

References (41)

1. Kasper CK, Kipnis SA. Hepatitis and clotting factor concentrates. J Am Med Assoc 1972, 221:510.
2. Ragni MV, Ndimbie OK, Rice EO, Bontempo FA, Nedjar S. Presence of antibody to hepatitis C virus (HCV) in hemophilic men with HCV 'seroreversion'. Blood 1993, 82:1010-5.
3. Ragni MV, Belle SH. Impact of human immunodeficiency virus (HIV) on progression to end-stage liver disease in individuals with hemophilia and hepatitis C. J Infect Dis 2001, 183:1112-5.
4. Hay CRM, Preston FE, Triger DR, Underwood JCE. Progressive liver disease in hemophilia: an understated problem? Lancet 1985, 1:1495-8.
5. Ragni MV, Bontempo FA, Faruki H. Increase in hepatitis C viral load in hemophiliacs treated with highly-active antiretroviral therapy. J Infect Dis 1999, 180:2027-9.
6. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009, 15:552-8.
7. Ragni MV, Moore CG, Soadwa K. Impact of HIV on hepatitis C infection in hemophilia: prevalence and predictors of liver fibrosis. Hepatology 2008, 48. abstract)
8. Ragni MV, Belle SH, Im K. Survival in HIV-infected liver transplant recipients. J Infect Dis 2003, 188:1412-20.
9. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung J. Pre-transplant survival is shorter in HIV-positive than in HIV-negative subjects with end-stage liver disease. Liver Transpl 2005, 11:1425-30.
10. Ragni MV, DeVera ME, Roland M. Outcomes in HIV/HCV hemophilic vs. non-hemophilic transplant candidates. 2010, 17th Annual Conference on Retroviruses and Opportunistic Infections (CROI, Q-1006 (abstract
11. Subramanian A, Sulkowski M, Barin B. MELD is an important predictor of pre-transplant mortality in HIV-infected liver transplant candidates. Gastroenterology 2010, 138:159-64.
12. Fung JF, Eghtesad B, Patel TK, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004, 10(Suppl. 2):S39-53.
13. DeVera ME, Dvorchik I, Tom K. Survival of liver transplant patients co-infected with HIV and HCV: the impact of recurrent hepatitis C. Am J Transplant 2006, 6:2983-93.
14. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006, 44:15-22.
15. Saito T, Gale M. Regulation of innate immunity against hepatitis C virus infection. Hepatol Res 2008, 38:115-22.
16. Keller BC, Johnson CL, Erickson AK, Gale M. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007, 18:535-44.
17. Johnson CL, Owen DM, Gale M. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 2007, 282:10792-803.
18. Mann EA, Stanford S, Sherman KE. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation. Virus Res 2006, 121:51-7.
19. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979-98.
20. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008, 10:821-7.
21. Fried M, Shiffman M, Reddy R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
22. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65.
23. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008, 46:78-84.
24. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-52.
25. Hezode C, Forestier N, Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-50.
26. McHutchison JG, Everson GT, Gordon SC. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-38.
27. Kieffer TL, Sarrazin C, Miller JS. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631-9.
28. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009, 18:709-25.
29. Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009, 13:403-17.
30. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. Br Med J 1990, 300:1166-70.
31. Cooling LL, Koerner TA, Naides SJ. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 1995, 172:1198-205.
32. Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990, 75:603-10.
33. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998, 75:97-102.
34. Robertson BH, Erdman DD. Non-enveloped viruses transmitted by blood and blood products. Dev Biol Stand 2000, 102:29-35.
35. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993, 31:323-8.
36. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine: summary of a workshop. Transfusion 2001, 41:130-5.
37. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994, 343:211-2.
38. Bonvicini F, Gallinella G, Cricca M. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus. J Med Virol 2004, 74:272-6.
39. Clewley JP. Biochemical characterization of a human parvovirus. J Gen Virol 1984, 65:241-5.
40. Weimer T, Streichert S, Watson C, Groner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001, 41:1500-4.
41. Kleinman SH, Glynn SA, Lee TH. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009, 114:3677-83.